What is JIN MEDICAL INTERNATIONAL LTD.'s earnings per share (EPS)?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) reported diluted earnings per share of $0.01 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) Financials

ZJYL

FY2025 annual

Revenue $20.7M -12.0% YoY

Net Income $1.2M -67.6% YoY

EPS (Diluted) $0.01 YoY not available

Free Cash Flow -$3.7M -175.6% YoY

Market Cap $152.5M as of Sep 12, 2026

Price / Sales 7.4x on $20.7M revenue, FY2025

Price / Earnings 128x on $1.2M net income, FY2025

Price / Book 5.1x on $29.6M equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Sep 30, 2025 Reported Feb 10, 2026 Currency USD FYE September

Newest figures come from the 20-F for FY2025, filed Feb 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ZJYL SEC filings page.

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) reported $20.7M in revenue for fiscal year 2025, down 12.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ZJYL FY2025 2026-08-30

FY2025 reveals a capital-intensive reset: weaker margins and heavier leverage offset revenue scale while operating cash flow stayed positive

Operating cash flow recovered to $2.9M in FY2025 even as net income was only $1.2M, after cash flow had been negative in FY2024; the reversal means working-capital timing or other non-earnings items materially shaped cash generation. Free cash flow remained negative at -$3.7M because capital expenditures reached $6.6M, so positive operating cash did not translate into cash after reinvestment.

Revenue fell 12.0% in FY2025 while gross margin compressed by 11.2 percentage points; that combination points to weaker economics per sale, not merely lower volume.

Debt-to-equity rose from 0.6x to 0.8x, marking a more leveraged funding structure. Current ratio fell from 2.5x to 1.9x, leaving less short-term balance-sheet flexibility.

Financial Health Signals

Financial Health Score 46/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of JIN MEDICAL INTERNATIONAL LTD.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

JIN MEDICAL INTERNATIONAL LTD. has an operating margin of 2.9%, meaning the company retains $3 of operating profit per $100 of revenue. This results in a moderate score of 63/100, indicating healthy but not exceptional operating efficiency. This is down from 15.5% the prior year.

Growth

JIN MEDICAL INTERNATIONAL LTD.'s revenue declined 12.0% year-over-year, from $23.5M to $20.7M. This contraction results in a growth score of 38/100.

Leverage

JIN MEDICAL INTERNATIONAL LTD. has a moderate D/E ratio of 0.80. This balance of debt and equity financing earns a leverage score of 52/100.

Liquidity

JIN MEDICAL INTERNATIONAL LTD.'s current ratio of 1.86 indicates adequate short-term liquidity, earning a score of 55/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While JIN MEDICAL INTERNATIONAL LTD. generated $2.9M in operating cash flow, capex of $6.6M consumed most of it, leaving -$3.7M in free cash flow. This results in a low score of 13/100, reflecting heavy capital investment rather than weak cash generation.

Returns

JIN MEDICAL INTERNATIONAL LTD.'s ROE of 4.0% shows moderate profitability relative to equity, earning a score of 56/100. This is down from 12.8% the prior year.

Altman Z-Score Safe

5.28

JIN MEDICAL INTERNATIONAL LTD. scores 5.28, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($152.5M) relative to total liabilities ($23.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

JIN MEDICAL INTERNATIONAL LTD. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

2.44x

For every $1 of reported earnings, JIN MEDICAL INTERNATIONAL LTD. generates $2.44 in operating cash flow ($2.9M OCF vs $1.2M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

None of these metrics is reported for Q4 2025.

Cash & Balance Sheet

Cash & Debt

$7.5M

YoY-8.3%

QoQ-33.0%

JIN MEDICAL INTERNATIONAL LTD. held $7.5M in cash as of Q4 2025; long-term debt is not reported for that period.

Shares Outstanding

157M

YoY0.0%

QoQ0.0%

JIN MEDICAL INTERNATIONAL LTD. had 157M shares outstanding in Q4 2025. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q4 2025.

Dividends Per Share

Not reported for Q4 2025.

Margins & Returns

None of these metrics is reported for Q4 2025.

Capital Allocation

None of these metrics is reported for Q4 2025.

ZJYL Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZJYL quarterly income statement

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K
Revenue	$20.7M-12.0%	$23.5M+18.6%	$19.8M+3.3%	$19.2M-7.6%	$20.8M
Cost of Revenue	$14.4M+4.0%	$13.9M+8.1%	$12.9M+0.2%	$12.8M-10.9%	$14.4M
Gross Profit	$6.0M-36.4%	$9.5M+40.1%	$6.8M+9.5%	$6.2M-2.6%	$6.4M
R&D Expenses	$1.6M+4.0%	$1.5M-3.0%	$1.5M-18.5%	$1.9M+20.8%	$1.6M
SG&A Expenses	$2.5M-22.3%	$3.3M+69.8%	$1.9M+8.3%	$1.8M+6.0%	$1.7M
Operating Income	$608K-83.3%	$3.6M+26.9%	$2.9M+34.6%	$2.1M-19.0%	$2.6M
EBITDA	$852K-78.0%	$3.9M+25.3%	$3.1M+24.1%	$2.5M-16.3%	$3.0M
Interest Expense	N/A	N/A	$183K+0.6%	$182K+2013.2%	-$9K
Income Tax	$215K-71.9%	$764K+122.2%	$344K+851.8%	$36K-85.5%	$249K
Net Income	$1.2M-67.6%	$3.7M+27.7%	$2.9M+6.3%	$2.7M+2.8%	$2.6M
EPS (Basic)	$0.01-50.0%	$0.020.0%	$0.020.0%	$0.020.0%	$0.02
EPS (Diluted)	$0.01	$0.020.0%	$0.020.0%	$0.020.0%	$0.02
Diluted Shares (Avg)	157M	156M+7.8%	145M+7.5%	135M0.0%	135M

Metric	Q4'2520-F	Q2'256-K	Q4'2420-F	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q4'2210-K

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).

ZJYL Balance Sheet

ZJYL quarterly balance sheet

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K
Total Assets	$53.4M+16.5%	$45.8M+39.2%	$32.9M+57.1%	$20.9M	N/A
Current Assets	$44.1M+3.1%	$42.8M+37.6%	$31.1M+64.6%	$18.9M	N/A
Cash & Equivalents	$7.5M-8.3%	$8.1M+17.4%	$6.9M+44.6%	$4.8M+30.5%	$3.7M
Short-Term Investments	$22.2M+19.1%	$18.6M+90.6%	$9.8M+329.2%	$2.3M	$0
Inventory	$4.9M-4.8%	$5.2M+2.4%	$5.1M-24.9%	$6.7M	N/A
Accounts Receivable	$5.8M-1.8%	$5.9M+80.1%	$3.3M-14.3%	$3.8M	N/A
Long-Term Investments	$0	$0	$0	$0	$0
Total Liabilities	$23.8M+38.0%	$17.2M+93.3%	$8.9M+56.5%	$5.7M	N/A
Current Liabilities	$23.8M+38.7%	$17.2M+92.2%	$8.9M+56.5%	$5.7M	N/A
Non-Current Liabilities	$0-100.0%	$96K	$0	$0	N/A
Total Equity	$29.6M+2.9%	$28.8M+20.2%	$24.0M+57.4%	$15.2M+8.6%	$14.0M
Retained Earnings	$20.9M+4.6%	$20.0M+18.3%	$16.9M+17.5%	$14.4M	N/A

Metric	Q4'2520-F	Q2'256-K	Q4'2420-F	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q4'2210-K
Total Assets	$53.4M+16.5%	$48.5M+17.9%	$45.8M+39.2%	$41.2M+32.7%	$32.9M+57.1%	$31.0M	$20.9M
Current Assets	$44.1M+3.1%	$43.8M+14.7%	$42.8M+37.6%	$38.2M+31.2%	$31.1M+64.6%	$29.1M	$18.9M
Cash & Equivalents	$7.5M-8.3%	$11.1M+25.4%	$8.1M+17.4%	$8.9M+269.8%	$6.9M+44.6%	$2.4M	$4.8M
Short-Term Investments	$22.2M+19.1%	$19.8M+15.8%	$18.6M+90.6%	$17.1M+264.4%	$9.8M+329.2%	$4.7M	$2.3M
Inventory	$4.9M-4.8%	$4.5M-1.9%	$5.2M+2.4%	$4.5M-30.2%	$5.1M-24.9%	$6.5M	$6.7M
Accounts Receivable	$5.8M-1.8%	$4.2M+9.9%	$5.9M+80.1%	$3.9M+1221.3%	$3.3M-14.3%	$292K	$3.8M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$23.8M+38.0%	$20.8M+38.4%	$17.2M+93.3%	$15.0M+100.7%	$8.9M+56.5%	$7.5M	$5.7M
Current Liabilities	$23.8M+38.7%	$20.7M+39.9%	$17.2M+92.2%	$14.8M+98.3%	$8.9M+56.5%	$7.5M	$5.7M
Non-Current Liabilities	$0-100.0%	$30K-83.3%	$96K	$180K	$0	$0	$0
Total Equity	$29.6M+2.9%	$27.9M+6.4%	$28.8M+20.2%	$26.2M+11.5%	$24.0M+57.4%	$23.5M	$15.2M
Retained Earnings	$20.9M+4.6%	$19.9M+7.6%	$20.0M+18.3%	$18.5M+15.4%	$16.9M+17.5%	$16.0M	$14.4M

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

ZJYL Cash Flow Statement

ZJYL quarterly cash flow statement

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K
Operating Cash Flow	$2.9M+340.5%	-$1.2M-138.9%	$3.1M+96.5%	$1.6M-72.9%	$5.8M
Depreciation & Amortization	$243K+2.3%	$238K+5.3%	$226K-37.7%	$363K+4.6%	$347K
Capital Expenditures	$6.6M+4473.9%	$145K+27.2%	$114K+183.7%	$40K-6.3%	$43K
Free Cash Flow	-$3.7M-175.6%	-$1.4M-145.2%	$3.0M+94.3%	$1.5M-73.4%	$5.8M
Investing Cash Flow	-$10.8M-13.4%	-$9.5M-23.1%	-$7.7M-6293.7%	-$121K+88.7%	-$1.1M
Financing Cash Flow	$7.4M-36.9%	$11.7M+68.6%	$6.9M+5571.2%	$122K+104.2%	-$2.9M

Metric	Q4'2520-F	Q2'256-K	Q4'2420-F	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q4'2210-K

Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

ZJYL Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZJYL quarterly financial ratios

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K
Gross Margin	29.2%-11.2pp	40.4%+6.2pp	34.2%+1.9pp	32.3%+1.7pp	30.6%
Operating Margin	2.9%-12.5pp	15.5%+1.0pp	14.5%+3.4pp	11.1%-1.6pp	12.7%
Net Margin	5.8%-9.9pp	15.6%+1.1pp	14.5%+0.4pp	14.1%+1.4pp	12.7%
Return on Equity	4.0%-8.7pp	12.8%+0.8pp	12.0%-5.8pp	17.8%-1.0pp	18.8%
Return on Assets	2.2%-5.8pp	8.0%-0.7pp	8.8%-4.2pp	12.9%	N/A
Current Ratio	1.86-0.6x	2.50-1.0x	3.49+0.2x	3.31	N/A
Debt-to-Equity	0.80+0.2x	0.60+0.2x	0.370.0x	0.37	N/A
Asset Turnover	0.39-0.1x	0.51-0.1x	0.60-0.3x	0.92	N/A
FCF Margin	-18.0%-12.3pp	-5.8%-20.8pp	15.1%+7.1pp	8.0%-19.9pp	27.9%

Metric	Q4'2520-F	Q2'256-K	Q4'2420-F	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q4'2210-K
Current Ratio	1.86-0.6x	2.11-0.5x	2.50-1.0x	2.58-1.3x	3.49+0.2x	3.89	3.31
Debt-to-Equity	0.80+0.2x	0.74+0.2x	0.60+0.2x	0.57+0.3x	0.370.0x	0.32	0.37

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
JIN MEDICAL INTERNATIONAL LTD. ZJYL	FY2025	$20.7M	$1.2M	5.8%	$152.5M	46/100
Pro-Dex Inc New PDEX	FY2026	$77.5M	$13.7M	17.6%	$201.2M	72/100
Utah Medical Products Inc UTMD	FY2025	$38.5M	$11.3M	29.3%	$221.9M	78/100
KORU Medical Systems, Inc. KRMD	FY2025	$41.1M	-$2.6M	-6.4%	$145.9M	66/100
Anteris Technologies Global Corp. AVR	FY2025	$1.9M	-$94.1M	N/A	$813.8M	22/100

Where JIN MEDICAL INTERNATIONAL LTD. Ranks

Frequently Asked Questions

What is JIN MEDICAL INTERNATIONAL LTD.'s annual revenue?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) reported $20.7M in total revenue for fiscal year 2025. This represents a -12.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is JIN MEDICAL INTERNATIONAL LTD.'s revenue growing?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) revenue declined by 12.0% year-over-year, from $23.5M to $20.7M in fiscal year 2025.

Is JIN MEDICAL INTERNATIONAL LTD. profitable?

Yes, JIN MEDICAL INTERNATIONAL LTD. (ZJYL) reported a net income of $1.2M in fiscal year 2025, with a net profit margin of 5.8%.

What is JIN MEDICAL INTERNATIONAL LTD.'s EBITDA?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had EBITDA of $852K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is JIN MEDICAL INTERNATIONAL LTD.'s gross margin?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had a gross margin of 29.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is JIN MEDICAL INTERNATIONAL LTD.'s operating margin?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had an operating margin of 2.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is JIN MEDICAL INTERNATIONAL LTD.'s net profit margin?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had a net profit margin of 5.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is JIN MEDICAL INTERNATIONAL LTD.'s return on equity (ROE)?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) has a return on equity of 4.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is JIN MEDICAL INTERNATIONAL LTD.'s free cash flow?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) recorded an outflow of $3.7M in free cash flow during fiscal year 2025. This represents a -175.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is JIN MEDICAL INTERNATIONAL LTD.'s operating cash flow?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) generated $2.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are JIN MEDICAL INTERNATIONAL LTD.'s total assets?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had $53.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are JIN MEDICAL INTERNATIONAL LTD.'s capital expenditures?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) invested $6.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does JIN MEDICAL INTERNATIONAL LTD. spend on research and development?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) invested $1.6M in research and development during fiscal year 2025.

How many shares does JIN MEDICAL INTERNATIONAL LTD. have outstanding?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had 157M shares outstanding as of fiscal year 2025.

What is JIN MEDICAL INTERNATIONAL LTD.'s current ratio?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had a current ratio of 1.86 as of fiscal year 2025, which is generally considered healthy.

What is JIN MEDICAL INTERNATIONAL LTD.'s debt-to-equity ratio?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had a debt-to-equity ratio of 0.80 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is JIN MEDICAL INTERNATIONAL LTD.'s return on assets (ROA)?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had a return on assets of 2.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is JIN MEDICAL INTERNATIONAL LTD.'s P/E ratio?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) trades at 128x earnings, its market capitalization divided by net income of $1.2M net income, FY2025. The market capitalization is $152.5M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is JIN MEDICAL INTERNATIONAL LTD.'s price-to-sales ratio?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) trades at 7.4x sales, its market capitalization divided by revenue of $20.7M revenue, FY2025. The market capitalization is $152.5M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is JIN MEDICAL INTERNATIONAL LTD.'s Altman Z-Score?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) has an Altman Z-Score of 5.28, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is JIN MEDICAL INTERNATIONAL LTD.'s Piotroski F-Score?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are JIN MEDICAL INTERNATIONAL LTD.'s earnings high quality?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) has an earnings quality ratio of 2.44x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is JIN MEDICAL INTERNATIONAL LTD.?

JIN MEDICAL INTERNATIONAL LTD. (ZJYL) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.